FDA Device recall Z-1706-2017
Mobile Diagnostic X-Ray System with Digital Panel
- FDA Device
- Class II
- terminated
- Published 2017-04-12
On 2017-04-12 the FDA classified a Class II recall of Mobile Diagnostic X-Ray System with Digital Panel by Philips Healthcare, citing when the operator moves an image to another view then the electronic marker might be placed at the wrong anatomical position in the resulting image.
Read the official FDA Device notice
| Agency | FDA Device |
|---|---|
| Recall number | Z-1706-2017 |
| Classification | Class II |
| Status | terminated |
| Initiated | 2012-11-28 |
| Published | 2017-04-12 |
| Last updated | 2026-09-13 11:54 UTC |
| Company | Philips Healthcare |
| Distribution | US |
Product
Mobile Diagnostic X-Ray System with Digital Panel
Reason
When the operator moves an image to another view then the electronic marker might be placed at the wrong anatomical position in the resulting image.
Identifiers
| code_info | *** All units *** |
|---|
Status history
No status changes recorded since RecallRadar first saw this recall on 2026-09-13 11:54 UTC. Current status: terminated.
Other recalls by Philips Healthcare
- Incisive CT, software version 5.0
FDA Device · Class II · 2023-10-11 · Philips Healthcare - Philips StentBoost Live R2.0 application, when used with the Philips Azurion with software release R2.x
FDA Device · Class II · 2022-04-13 · Philips Healthcare - Azurion systems with software release R2.0.x
FDA Device · Class II · 2022-03-30 · Philips Healthcare - CombiDiagnost R90 is multi-functional general R/F systems
FDA Device · Class II · 2021-12-01 · Philips Healthcare - Philips Azurion systems with software releases 2.1(L1) and 2.1(L2)
FDA Device · Class II · 2021-12-01 · Philips Healthcare
All Philips Healthcare recalls
Source
Official record: https://api.fda.gov/device/enforcement.json?search=recall_number:%22Z-1706-2017%22
RecallRadar indexes public recall notices from the FDA, USDA FSIS, and CPSC. The official agency notice is the authoritative source. Always confirm details at the linked source before acting.